Effects of proteasome inhibitors on leukemias / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 896-900, 2007.
Artigo
em Chinês
| WPRIM
| ID: wpr-276797
ABSTRACT
The proteasome is primarily responsible for intracellular protein degradation. The abnormality of its activity is sign of tumorigenesis. It was confirmed that proteasome inhibitors have activities against a variety of malignancies. Bortezomib, the first proteasome inhibitor, obtained permission of clinical trial and on sale. Multiple myeloma patients treated with bortezomib have gained a high overall response rate and complete remission rate. A lot of studies on effects of proteasome inhibitors on leukemias, including plasma cell leukemia; chronic lymphocytic leukemia, adult T cell lymphoma/leukemia, chronic myeloid leukemia and acute myeloid leukemia, were reviewed in this article.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Inibidores de Proteases
/
Pirazinas
/
Ácidos Borônicos
/
Leucemia
/
Usos Terapêuticos
/
Tratamento Farmacológico
/
Inibidores de Proteassoma
/
Bortezomib
/
Mieloma Múltiplo
Limite:
Animais
/
Humanos
Idioma:
Chinês
Revista:
Journal of Experimental Hematology
Ano de publicação:
2007
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS